ACADIA Pharmaceuticals Inc.

Quick facts

Phase 3 pipeline

• ACP-204 · Psychiatry / Neurology
  ACP-204 is a muscarinic M1 receptor agonist that enhances cholinergic neurotransmission to improve cognitive and psychiatric symptoms.

Phase 2 pipeline

• ACP-104 · Neurology
  ACP-104 is a selective histamine H3 receptor inverse agonist.
• ACP-211 · Neurology
  ACP-211 is a selective histamine H3 receptor inverse agonist.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• ACADIA Pharmaceuticals Inc. portfolio CI brief
• ACADIA Pharmaceuticals Inc. pipeline updates RSS